NIBEC Co., Ltd. (KOSDAQ:138610)
South Korea · Delayed Price · Currency is KRW 30,850
-1,600 (-4.93%)
At close: Feb 6, 2026
NIBEC Revenue
NIBEC had revenue of 5.17B KRW in the quarter ending September 30, 2025, a decrease of -10.67%. This brings the company's revenue in the last twelve months to 32.96B, up 44.48% year-over-year. In the year 2024, NIBEC had annual revenue of 24.55B with 56.33% growth.
Revenue (ttm)
32.96B
Revenue Growth
+44.48%
P/S Ratio
10.64
Revenue / Employee
343.34M
Employees
96
Market Cap
350.61B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 24.55B | 8.85B | 56.33% |
| Dec 31, 2023 | 15.70B | -5.97B | -27.53% |
| Dec 31, 2022 | 21.67B | 8.05B | 59.04% |
| Dec 31, 2021 | 13.63B | 7.27B | 114.33% |
| Dec 31, 2020 | 6.36B | -2.93B | -31.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GC Cell | 170.13B |
| ISU Abxis | 66.39B |
| Genome & Company | 25.95B |
| S.Biomedics | 16.96B |
| Prestige Biologics | 13.36B |
| QuadMedicine | 13.11B |
| Y-Biologics | 3.61B |
| Vaxcell-Bio Therapeutics | 1.90B |